Idioma:

Colchicine in High-risk Patients with Acute Minor-to-moderate Ischemic Stroke or Transient Ischemic Attack (CHANCE-3): Rationale and design of a multicenter randomized placebo-controlled trial

Wang, Yongjun ; Li, Jiejie ; Johnston, S Claiborne ; Hankey, Graeme J ; Easton, J Donald ; Meng, Xia ; Shi, Fu-Dong ; Wang, Yilong ; Zhao, Xingquan ; Li, Zixiao ; Liu, Liping ; Gu, Hongqiu ; Jiang, Yong ; Wang, Anxin ; Pan, Yuesong ; Jing, Jing ; Niu, Siying ; Li, Hao

International journal of stroke, 2023-08, Vol.18 (7), p.873-878 [Periódico revisado por pares]

London, England: SAGE Publications

Texto completo disponível

Citações Citado por

Enviar para

Título:
Colchicine in High-risk Patients with Acute Minor-to-moderate Ischemic Stroke or Transient Ischemic Attack (CHANCE-3): Rationale and design of a multicenter randomized placebo-controlled trial
Autor: Wang, Yongjun ; Li, Jiejie ; Johnston, S Claiborne ; Hankey, Graeme J ; Easton, J Donald ; Meng, Xia ; Shi, Fu-Dong ; Wang, Yilong ; Zhao, Xingquan ; Li, Zixiao ; Liu, Liping ; Gu, Hongqiu ; Jiang, Yong ; Wang, Anxin ; Pan, Yuesong ; Jing, Jing ; Niu, Siying ; Li, Hao
Assuntos: Aspirin - therapeutic use ; Clopidogrel - therapeutic use ; Colchicine - therapeutic use ; Humans ; Ischemic Attack, Transient - drug therapy ; Ischemic Stroke - drug therapy ; Platelet Aggregation Inhibitors - therapeutic use ; Stroke - chemically induced ; Stroke - drug therapy
É parte de: International journal of stroke, 2023-08, Vol.18 (7), p.873-878
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
Descrição: Background: Anti-inflammatory therapy using colchicine has reduced recurrent vascular events in patients with coronary heart disease. Design: Colchicine in High-risk Patients with Acute Minor-to-moderate Ischemic Stroke or Transient Ischemic Attack (CHANCE-3) is a randomized, double-blind, placebo-controlled multicenter trial, in which 8,238 patients with acute minor-to-moderate ischemic stroke (NIHSS ⩽ 5) or high-risk transient ischemic attack (TIA) (ABCD2 score ⩾4) and a high-sensitivity CRP (hsCRP) level of ⩾2 mg/L will be randomly assigned within 24 h of symptom onset to colchicine (1 mg daily on days 1–3, followed by 0.5 mg daily for a total of 90 days) or matching placebo, on a background of optimal medical therapy. The study will have 90% power to detect a 25% reduction in the primary efficacy outcome of any stroke within 3 months of randomization. Adverse events potentially related to the use of colchicine will also be analyzed. The primary analysis will be by intention to treat. Trial registry name: Colchicine in High-risk Patients with Acute Minor-to-moderate Ischemic Stroke or Transient Ischemic Attack (CHANCE-3); URL: https://clinicaltrials.gov/ct2/show/NCT05439356?cond=CHANCE-3&draw=2&rank=1; Registration number: NCT05439356.
Editor: London, England: SAGE Publications
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Colchicine in High-risk Patients with Acute Minor-to-moderate Ischemic Stroke or Transient Ischemic Attack (CHANCE-3): Rationale and design of a multicenter randomized placebo-controlled trial

Wang, Yongjun ; Li, Jiejie ; Johnston, S Claiborne ; Hankey, Graeme J ; Easton, J Donald ; Meng, Xia ; Shi, Fu-Dong ; Wang, Yilong ; Zhao, Xingquan ; Li, Zixiao ; Liu, Liping ; Gu, Hongqiu ; Jiang, Yong ; Wang, Anxin ; Pan, Yuesong ; Jing, Jing ; Niu, Siying ; Li, Hao

London, England: SAGE Publications

Buscando em bases de dados remotas. Favor aguardar.